DGAP-News: Neovacs S.A. / Key word(s): Conference
Neovacs to present at two major Investor Conferences
30.08.2016 / 08:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Neovacs to present at two major Investor Conferences
The 18th Annual Rodman & Renshaw Global Investment Conference & BIO-Europe
2016
Paris and Boston, August 30, 2016 - Neovacs (Alternext Paris: ALNEV) a
leader in active immunotherapy for the treatment of autoimmune diseases,
today announced that CEO Miguel Sieler will present at both the 18th Annual
Rodman & Renshaw Global Investment Conference and BIO-Europe 2016.
The Rodman & Renshaw Global Investment Conference, being held September 11-
13 in New York, USA will host over 265 public and private companies and
several thousand attendees. The conference will bring together a vast
audience of financial and strategic investors with growth companies in the
fields of healthcare, natural resources, technology, media,
telecommunications, and cleantech. In addition to corporate presentations,
the conference facilitates one-on-one meetings with members of the
investment community.
Miguel Sieler, CEO of Neovacs, will present the company and recent updates
at Rodman & Renshaw on Monday September 12, from 10:50 to 11:15 am EST at
the New York Palace Hotel, on the fourth floor in the Louis Room.
Neovacs will also present at BIO-Europe, which will take place November 7-9
in Cologne, Germany. This conference is one of the world's most important
meetings for the biotech Industry. This year the BIO-Europe event will draw
over 3,500 attendees from 60 countries, representing 1,800 companies. It
will provide Neovacs with the opportunity to meet a vast audience of
financial and strategic investors, as well as potential high-level
partners.
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus and dermatomyositis. Neovacs is
also conducting preclinical development works on other therapeutic vaccines
in the fields of auto-immune diseases, oncology and allergies. The goal of
the Kinoid approach is to enable patients to have access to safe treatments
with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts
NEOVACS - Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com
Investor Relations / Financial Communication Germany - MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu
Press / U.S. Inquiries - The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
lroth@theruthgroup.com / jgreen@theruthgroup.com
---------------------------------------------------------------------------
30.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Neovacs S.A.
3-5, Impasse Reille
75014 Paris
France
Phone: +33 (0)1 53 10 93 00
Fax: +33 (0)1 53 10 93 03
E-mail: www.neovacs.fr
Internet: info@neovacs.fr
ISIN: FR0004032746
WKN: A1CVKR
Listed: Regulated Unofficial Market in Stuttgart; Open Market in
Frankfurt
End of News DGAP News Service
---------------------------------------------------------------------------
496637 30.08.2016
DGAP-News: Neovacs to present at two major Investor Conferences
| Source: EQS Group AG